Target intelligence / Profile preview

T cell receptor alpha joining 32 (TRAJ32)

Target
TRAJ32
Molecular classification
Receptor (T cell receptor component), Other (Joining gene segment)
01

Overview

T cell receptor alpha joining 32 (TRAJ32) is one of the joining (J) gene segments that encode a portion of the T cell receptor (TCR) alpha chain in humans[1][4][7]. TCRs are heterodimeric (alpha-beta or gamma-delta) membrane proteins on T lymphocytes responsible for recognizing antigens that are presented as peptide-MHC (major histocompatibility complex) complexes on antigen-presenting cells[1][7]. TCR alpha chains are generated by somatic recombination of variable (V), joining (J), and constant (C) gene segments. The TRAJ32 segment specifically contributes to the antigen-binding diversity of the TCR but does not encode a functional protein by itself; it is only active as part of the larger recombined receptor[1][4]. There is no evidence that TRAJ32 is a direct therapeutic target or interacts with drugs as an isolated gene segment. Its biological significance is in immune recognition and adaptive immunity as a sequence contributor to TCR diversity[1][7][6].

Other names
TRAJ32
02

Biological functions

Antigen recognition (as part of the T cell receptor)Adaptive immune response
03

Disease associations

Other (Component of immune surveillance; no direct disease linkage as an individual gene segment)

Beyond the preview

Go deeper on T cell receptor alpha joining 32 (TRAJ32).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor alpha joining 32 (TRAJ32).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call